Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

459789-99-2 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Obeticholic Acid
Cas No: 459789-99-2
No Data 1 Gram 30 Kilogram/Month Shanghai Hope Chem Co., Ltd Contact Supplier
Obeticholic acid, high purity
Cas No: 459789-99-2
USD $ 4000.0-4900.0 / Gram 100 Gram 100 Kilogram/Month Beijing Mesochem Technology Co.,LTD Contact Supplier
Obeticholic acid
Cas No: 459789-99-2
USD $ 100.0-100.0 / Gram 1 Gram 100 Kilogram/Month coolpharm Ltd Contact Supplier
Obeticholic Acid
Cas No: 459789-99-2
No Data 1 Gram 100 Kilogram/Month ningbo easun bio-tech co., ltd Contact Supplier
Obeticholic Acid
Cas No: 459789-99-2
No Data 10 Gram 100 Kilogram/Month Jinan Xinke Pharmaceutical Science and Technology Co., Ltd. Contact Supplier
Obeticholic Acid,6-Ethylchenodeoxycholic acid
Cas No: 459789-99-2
USD $ 1000.0-1000.0 / Gram 1 Gram 100 Kilogram/Month Ningbo Yinzhou Aurum Import & Export Co., Ltd. Contact Supplier
Obeticholic Acid
Cas No: 459789-99-2
No Data No Data Metric Ton/Day Shanghai Yanchu chemicals Co., Ltd Contact Supplier
6-Ethylchenodeoxycholic acid
Cas No: 459789-99-2
No Data No Data Metric Ton/Day Suzhou Howsine Biological Technology Co.,Ltd Contact Supplier
Obeticholic Acid
Cas No: 459789-99-2
No Data No Data Metric Ton/Day Shanghai Biobond Pharmaceutical Co.,Ltd Contact Supplier
6-Ethylchenodeoxycholic acid
Cas No: 459789-99-2
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier

459789-99-2 Usage

Mechanisms of Action

Obeticholic acid belongs to FXR stimulants, activating FXRs and indirectly inhibiting Cytochrome P450 Family 7 Subfamily A Member 1 (CYP7A1) expression. As CYP7A1 is a rate-limiting enzyme of bile acid biosynthesis, obeticholic acid can inhibit the bile acid synthesis and is used to treat primary biliary cirrhosis.

Indications and Usage

Obeticholic acid is also called 6-Ethylchenodeoxycholic acid. It is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids, a natural ligand for farnesoid x receptors (FXR). Obeticholic acid was developed by American pharmaceutical company Intercept as the first drug to treat cholestatic liver disease in 20 years, and it is administered on patients that do not respond well to or cannot tolerate the old standard treatment drug ursodeoxycholic acid. Obeticholic acid has also been tested to treat a more common form of fatty liver – non-alcoholic fatty liver disease (NAFLD). Obeticholic acid can also be developed to treat other liver and intestine diseases.


Verbeke, L, et al. "Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats."Hepatology 59.6(2014):2286-98.
Silveira, M. G., and K. D. Lindor. "Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis." Expert Opinion on Pharmacotherapy 15.3(2014):365.


Obeticholic acid is a semi-synthetic bile acid analogue and acts as a farnesoid-X receptor (FXR) agonist. It is used for the treatment of primary biliary cholangitis. It is also under investigation for the treatment of other liver diseases,primary biliary cirrhosis, bile acid diarrhea and related disorders. Study has shown that it also has potential for treating nonalcoholicsteatohepatitis (NASH), and portal hypertension. Obeticholic acid takes effect through acting s the agonist of the farnesoid X receptor (FXR), which is the regulator of bile and cholesterol metabolism in the liver. 

Clinical Research

In a placebo control phase III clinical trial, Obeticholic acid increased levels of two biomarkers indicating lowered risk in liver transplant. The composite end point of the clinical research is that alkaline phosphatase lowered by at least 15%, serum alkaline phosphatase activity was 1.67 times lower than the normal upper limit, and bilirubin levels were within normal range; alkaline phosphatase is a biomarker indicating liver disease severity. An American 6-week, multi-center, randomized, and double-blind clinical trial included 64 cases of type 2 diabetes patients with NAFLD, and it proved that Obeticholic acid not only increased insulin sensitivity, but also improved liver inflammation and fibrosis levels, and it has certain weight-reducing effects. However, this conclusion requires further investigation with a larger and more long-term follow-up, as well as scientific backing in liver pathology.


ChEBI: A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatme t of primary biliary cholangitis.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017


1.1 GHS Product identifier

Product name (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

1.2 Other means of identification

Product number -
Other names 6-ECDCA

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:459789-99-2 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields